{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:56:51Z","timestamp":1781636211896,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Endophthalmitis is a rare but vision-threatening complication of intravitreal injections. Intravitreal dexamethasone implants and anti\u2013vascular endothelial growth factor (anti-VEGF) agents are widely used, yet comparative real-world endophthalmitis rates remain incompletely defined. This study aimed to compare the incidence of endophthalmitis following intravitreal dexamethasone implant injections with that following anti-VEGF injections administered in outpatient retina practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included all intravitreal injections performed between January 2019 and January 2024 at participating practices. Endophthalmitis events consistent with post-injection exogenous endophthalmitis occurring within two weeks of intravitreal injection were identified through clinical records. Chi-square testing was used to compare incidence rates between dexamethasone implant and anti-VEGF injections. Patient characteristics, visual acuity outcomes, and treatment approaches were assessed for confirmed endophthalmitis cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 330,572 intravitreal injections were analyzed, including 318,618 anti-VEGF injections and 11,954 dexamethasone implant injections. Endophthalmitis occurred more frequently after dexamethasone implant injections (0.125%, 15\/11,954; 1.25 per 1,000 injections) than after anti-VEGF injections (0.033%, 106\/318,618; 0.33 per 1,000 injections). This difference was statistically significant (\u03c7\u00b2 = 23.45,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20092.3\u2009\u00d7\u200910\u207b\u2077). Among dexamethasone-associated cases, 46.7% recovered to baseline or better visual acuity by six months, while the remaining patients experienced persistent visual deficits. Management commonly included intravitreal antibiotics with or without adjunct corticosteroids.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intravitreal dexamethasone implant injections were associated with a significantly higher incidence of endophthalmitis compared with anti-VEGF injections in this large outpatient cohort. Although nearly half of affected patients regained baseline vision, many had lasting impairment. These findings highlight the need for careful risk\u2013benefit assessment when selecting intravitreal dexamethasone implants and underscore the importance of further study into modifiable risk factors and prevention strategies. A key limitation to consider is that clinically diagnosed endophthalmitis may include sterile intraocular inflammatory reactions following dexamethasone implant injection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-026-00824-3","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T01:15:19Z","timestamp":1771809319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative incidence of endophthalmitis after intravitreal dexamethasone implant versus anti-VEGF injections: a retrospective study"],"prefix":"10.1186","volume":"12","author":[{"given":"Iza D.","family":"Zabaneh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanner","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kortney","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"824_CR1","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/IAE.0b013e3180323f96","volume":"27","author":"CA Lemley","year":"2007","unstructured":"Lemley CA, Han DP. Endophthalmitis: a review of current evaluation and management. Retina. 2007;27:662\u201380. https:\/\/doi.org\/10.1097\/IAE.0b013e3180323f96.","journal-title":"Retina"},{"key":"824_CR2","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1016\/j.ophtha.2015.07.005","volume":"122","author":"BL VanderBeek","year":"2015","unstructured":"VanderBeek BL, Bonaffini SG, Ma L. Association between intravitreal steroids and post-injection endophthalmitis rates. Ophthalmology. 2015;122:2311\u2013e23151. https:\/\/doi.org\/10.1016\/j.ophtha.2015.07.005.","journal-title":"Ophthalmology"},{"key":"824_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/1469-0691.12118","volume":"19","author":"ML Durand","year":"2013","unstructured":"Durand ML, Endophthalmitis. Clin Microbiol Infect. 2013;19:227\u201334. https:\/\/doi.org\/10.1111\/1469-0691.12118.","journal-title":"Clin Microbiol Infect"},{"key":"824_CR4","doi-asserted-by":"publisher","first-page":"xx","DOI":"10.1016\/j.ajo.2017.11.021","volume":"187","author":"N Relhan","year":"2018","unstructured":"Relhan N, Forster RK, Flynn HW Jr. Endophthalmitis: then and now. Am J Ophthalmol. 2018;187:xx\u2013xxvii. https:\/\/doi.org\/10.1016\/j.ajo.2017.11.021.","journal-title":"Am J Ophthalmol"},{"key":"824_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3928\/23258160-20140306-08","volume":"45","author":"JB Fileta","year":"2014","unstructured":"Fileta JB, Scott IU, Flynn HW Jr. Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina. 2014;45:143\u20139. https:\/\/doi.org\/10.3928\/23258160-20140306-08.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"824_CR6","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1136\/bjophthalmol-2015-307707","volume":"100","author":"N Rayess","year":"2016","unstructured":"Rayess N, Rahimy E, Shah CP, et al. Incidence and clinical features of post-injection endophthalmitis according to diagnosis. Br J Ophthalmol. 2016;100:1058\u201361. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307707.","journal-title":"Br J Ophthalmol"},{"key":"824_CR7","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.ophtha.2011.02.034","volume":"118","author":"CP Shah","year":"2011","unstructured":"Shah CP, Garg SJ, Vander JF, Brown GC, Kaiser RS, Haller JA. Post-Injection Endophthalmitis (PIE) Study Team. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology. 2011;118:2028\u201334. https:\/\/doi.org\/10.1016\/j.ophtha.2011.02.034.","journal-title":"Ophthalmology"},{"key":"824_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ajo.2015.04.013","volume":"160","author":"D Dossarps","year":"2015","unstructured":"Dossarps D, Bron AM, Koehrer P, Aho-Glele LS, Creuzot-Garcher C. Endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome. Am J Ophthalmol. 2015;160:17\u2013e251. https:\/\/doi.org\/10.1016\/j.ajo.2015.04.013.","journal-title":"Am J Ophthalmol"},{"key":"824_CR9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/IAE.0b013e3181a94f01","volume":"29","author":"GA Peyman","year":"2009","unstructured":"Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina. 2009;29:875\u2013912. https:\/\/doi.org\/10.1097\/IAE.0b013e3181a94f01.","journal-title":"Retina"},{"key":"824_CR10","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1097\/00006982-200410000-00002","volume":"24","author":"RD Jager","year":"2004","unstructured":"Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24:676\u201398. https:\/\/doi.org\/10.1097\/00006982-200410000-00002.","journal-title":"Retina"},{"key":"824_CR11","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1001\/jamaophthalmol.2018.3939","volume":"136","author":"F Baudin","year":"2018","unstructured":"Baudin F, Benzenine E, Mariet AS, et al. Association of acute endophthalmitis with intravitreal injections of corticosteroids or anti-vascular growth factor agents in a nationwide study in France. JAMA Ophthalmol. 2018;136:1352\u20138. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.3939.","journal-title":"JAMA Ophthalmol"},{"key":"824_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.ajo.2013.12.018","volume":"157","author":"NM Holekamp","year":"2014","unstructured":"Holekamp NM, Liu Y, Yeh WS, et al. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. Am J Ophthalmol. 2014;157:825\u2013e8331. https:\/\/doi.org\/10.1016\/j.ajo.2013.12.018.","journal-title":"Am J Ophthalmol"},{"key":"824_CR13","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","volume":"117","author":"JA Haller","year":"2010","unstructured":"Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134\u2013e11463. https:\/\/doi.org\/10.1016\/j.ophtha.2010.03.032.","journal-title":"Ophthalmology"},{"key":"824_CR14","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","volume":"121","author":"DS Boyer","year":"2014","unstructured":"Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904\u201314. https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.024.","journal-title":"Ophthalmology"},{"key":"824_CR15","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897\u2013908. https:\/\/doi.org\/10.1056\/NEJMoa1102673.","journal-title":"N Engl J Med"},{"issue":"4","key":"824_CR16","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/IAE.0b013e31820a67e4","volume":"31","author":"CA McCannel","year":"2011","unstructured":"McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31(4):654\u201361. https:\/\/doi.org\/10.1097\/IAE.0b013e31820a67e4.","journal-title":"Retina"},{"key":"824_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jamaophthalmol.2016.5883","volume":"135","author":"MS Stem","year":"2017","unstructured":"Stem MS, Todorich B, Yonekawa Y, et al. Incidence and visual outcomes of culture-proven endophthalmitis following dexamethasone intravitreal implant. JAMA Ophthalmol. 2017;135:379\u201382. https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.5883.","journal-title":"JAMA Ophthalmol"},{"key":"824_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/bjophthalmol-2019-313991","volume":"104","author":"B Rajesh","year":"2020","unstructured":"Rajesh B, et al. Safety of 6000 intravitreal dexamethasone implants. Br J Ophthalmol. 2020;104:39\u201346. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-313991.","journal-title":"Br J Ophthalmol"},{"key":"824_CR19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1177\/24741264221109376","volume":"6","author":"M Pancholy","year":"2022","unstructured":"Pancholy M, et al. Incidence and visual outcomes of endophthalmitis after intravitreal injection of dexamethasone implant vs ranibizumab. J Vitreoretin Dis. 2022;6:358\u201366. https:\/\/doi.org\/10.1177\/24741264221109376.","journal-title":"J Vitreoretin Dis"},{"key":"824_CR20","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1097\/IAE.0000000000003546","volume":"42","author":"AG Samuelson","year":"2022","unstructured":"Samuelson AG, et al. Clinical outcomes of patients with endophthalmitis after dexamethasone intravitreal implant. Retina. 2022;42:1915\u201320. https:\/\/doi.org\/10.1097\/IAE.0000000000003546.","journal-title":"Retina"},{"key":"824_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/IAE.0000000000004270","volume":"45","author":"MO Kiristioglu","year":"2025","unstructured":"Kiristioglu MO, et al. Nonpharmacological aspects of intravitreal dexamethasone implant injections: a retrospective study of 3430 injections and complications. Retina. 2025;45:95\u2013106. https:\/\/doi.org\/10.1097\/IAE.0000000000004270.","journal-title":"Retina"},{"key":"824_CR22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3928\/23258160-20210528-03","volume":"52","author":"DS Dhoot","year":"2021","unstructured":"Dhoot DS, et al. Rates of suspected endophthalmitis following intravitreal injections in clinical practices in the United States. Ophthalmic Surg Lasers Imaging Retina. 2021;52:312\u20138. https:\/\/doi.org\/10.3928\/23258160-20210528-03.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"824_CR23","unstructured":"Williams GA. Review of ophthalmology: IVT injections: health policy implications. Rev Ophthalmol. 2016. Accessed November 2024. http:\/\/www.reviewofophthalmology.com\/content\/d\/retinal_insider\/c\/48732."},{"key":"824_CR24","unstructured":"Lindstrom RL. Significant investments will continue to advance retinal disease field. Ocul Surg News. September 22, 2023. Accessed November 2024. https:\/\/www.healio.com."},{"key":"824_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013;27:787\u201394. https:\/\/doi.org\/10.1038\/eye.2013.107.","journal-title":"Eye (Lond)"},{"key":"824_CR26","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3928\/23258160-20151027-07","volume":"46","author":"SJ Garg","year":"2015","unstructured":"Garg SJ, Dollin M, Hsu J, Storey P, Vander JF. Effect of a strict no-talking policy during intravitreal injection on post-injection endophthalmitis. Ophthalmic Surg Lasers Imaging Retina. 2015;46:1028\u201334. https:\/\/doi.org\/10.3928\/23258160-20151027-07.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"824_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10792-007-9073-6","volume":"27","author":"A Safar","year":"2007","unstructured":"Safar A, Dellimore MC. Effect of povidone-iodine flush versus drops on conjunctival colonization before intravitreal injections. Int Ophthalmol. 2007;27:307\u201312. https:\/\/doi.org\/10.1007\/s10792-007-9073-6.","journal-title":"Int Ophthalmol"},{"key":"824_CR28","doi-asserted-by":"publisher","unstructured":"Friedman DA, Mason JO 3rd, Emond T, McGwin G Jr. Povidone-iodine contact time and lid speculum use during intravitreal injection. Retina. 2013;33:975\u201381. https:\/\/doi.org\/10.1097\/IAE.0b013e3182877585.","DOI":"10.1097\/IAE.0b013e3182877585"},{"key":"824_CR29","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1001\/jamaophthalmol.2016.2741","volume":"134","author":"AR Bhavsar","year":"2016","unstructured":"Bhavsar AR, Glassman AR, Stockdale CR, Jampol LM, Diabetic Retinopathy Clinical Research Network. Elimination of topical antibiotics for intravitreous injections and the importance of povidone-iodine: update from the Diabetic Retinopathy Clinical Research Network. JAMA Ophthalmol. 2016;134:1181\u20133. https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.2741.","journal-title":"JAMA Ophthalmol"},{"key":"824_CR30","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ophtha.2013.08.037","volume":"121","author":"P Storey","year":"2014","unstructured":"Storey P, Dollin M, Pitcher J, et al. Role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology. 2014;121:283\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.037.","journal-title":"Ophthalmology"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00824-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00824-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00824-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:39:51Z","timestamp":1781635191000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00824-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["824"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00824-3","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was exempt from full review by the Institutional Review Board (IRB) of the University of North Texas Health Science Center for the purpose of utilizing de-identified data. Accordingly, the need for informed consent was waived. In line with ethical guidelines for protecting patient privacy, the data was collected and analyzed using electronic medical records based on the Health Insurance Portability and Accountability Act (HIPAA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}